Healthy volunteers needed to test safety of experimental drug BEAM-103
NCT ID NCT07304791
First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 25 times
Summary
This early-stage study tests the safety of a new drug, BEAM-103, in 30 healthy adults aged 18 to 55. Participants receive one intravenous dose of either BEAM-103 or a placebo and are monitored for up to 4 months. The goal is to see if the drug is safe and how the body processes it, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Study Site
RECRUITINGLondon, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.